In a fresh blow, Biogen loses a big court fight with Mylan over its blockbuster Tecfidera patent
The rough road Biogen has been traveling during the first half of 2020 just got considerably more bumpy.
A federal judge has ruled that Biogen’s crucial ‘514 patent is invalid, leaving Mylan open to fielding a generic that would eat into blockbuster revenue that has fueled the company for years.
“Mylan has established by clear and convincing evidence that the asserted claims of the ’514 Patent are invalid for lack of written description,” ruled US District Judge Irene Keeley.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.